Therapy-related Acute Myeloid Leukemia is a clonal disorder caused by malignant transformation of a bone marrow-derived, self-renewing stem cell or progenitor, in which the disease arises from toxic exposures. This leads to a decreased rate of self-destruction and aberrant differentiation causing an accumulation in the organs and bone marrow by these myeloid cells. In order for Myeloid Leukemia to be considered acute the bone marrow must be greater than 20% leukemic blasts.
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Therapy-related Acute Myeloid Leukemia below!
For more information on how to use Laverne, please read the How to Guide.
We have 950 products for the study of Therapy-related Acute Myeloid Leukemia that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Chromatin Immunoprecipitation (ChIP), Immunohistochemistry from our catalog of antibodies and ELISA kits.
Therapy-related Acute Myeloid Leukemia is also known as T-aml, Treatment Related Acute Myeloid Leukemia, Treatment Related Aml, Treatment-related Acute Myelocytic Leukemia, Treatment-related Acute Myelogenous Leukemia.